In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients

• Maria Vassilakopoulou ,

  Contributed equally to this work with: Maria Vassilakopoulou, Taiwo Togun

  Affiliation Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America

  ⨯
• Taiwo Togun ,

  Contributed equally to this work with: Maria Vassilakopoulou, Taiwo Togun

  Affiliation Yale University, School of Public Health, Department of Biostatistics, New Haven, Connecticut, United States of America

  ⨯
• Urania Dafni,

  Affiliation Laboratory of Biostatistics, University of Athens School of Nursing, Athens, Greece

  ⨯
• Huan Cheng,

  Affiliation Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America

  ⨯
• Jennifer Bordeaux,

  Affiliation Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America

  ⨯
• Veronique M. Neumeister,

  Affiliation Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America

  ⨯
• Mattheos Bobos,

  Affiliation Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

  ⨯
• George Pentheroudakis,

  Affiliation Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece

  ⨯
• Dimosthenis V. Skarlos,

  Affiliation Second Department of Medical Oncology, “Metropolitan” Hospital, Piraeus, Greece

  ⨯
• Dimitrios Pectasides,

  Affiliation Oncology Section, Second Department of Internal Medicine, “Hippokration” Hospital, Athens, Greece

  ⨯
• Vassiliki Kotoula,

  Affiliations Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece, Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

  ⨯
• George Fountzilas,

  Affiliations Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece, Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

  ⨯
• David L. Rimm,

  Affiliation Yale University, School of Medicine, Department of Pathology, New Haven, Connecticut, United States of America

  ⨯
• Amanda Psyrri

  * E-mail: dpsyrri@med.uoa.gr

  Affiliation Division of Oncology, Second Department of Internal Medicine, University of Athens School of Medicine, Attikon University Hospital, Athens, Greece

  ⨯